TY - JOUR
T1 - Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor
AU - Montfort, William R.
AU - Wales, Jessica A.
AU - Weichsel, Andrzej
N1 - Funding Information:
This work was supported in part by grants from the National Institutes of Health (R01 GM117357 and P30 CA023074 to W.R.M., and T32 GM008804 to J.W.), the American Heart Association and the AHA Phoenix Heart Ball (14GRNT20080006 to W.R.M.), and a contract from Ironwood Pharmaceuticals (100003104 to W.R.M.).
Publisher Copyright:
© Copyright 2017, Mary Ann Liebert, Inc.
PY - 2017/1/20
Y1 - 2017/1/20
N2 - Significance: Soluble guanylyl/guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) and is central to the physiology of blood pressure regulation, wound healing, memory formation, and other key physiological activities. sGC is increasingly implicated in disease and is targeted by novel therapeutic compounds. The protein displays a rich evolutionary history and a fascinating signal transduction mechanism, with NO binding to an N-terminal heme-containing domain, which activates the C-terminal cyclase domains. Recent Advances: Crystal structures of individual sGC domains or their bacterial homologues coupled with small-angle x-ray scattering, electron microscopy, chemical cross-linking, and Förster resonance energy transfer measurements are yielding insight into the overall structure for sGC, which is elongated and likely quite dynamic. Transient kinetic measurements reveal a role for individual domains in lowering NO affinity for heme. New sGC stimulatory drugs are now in the clinic and appear to function through binding near or directly to the sGC heme domain, relieving inhibitory contacts with other domains. New sGC-activating drugs show promise for recovering oxidized sGC in diseases with high inflammation by replacing lost heme. Critical Issues: Despite the many recent advances, sGC regulation, NO activation, and mechanisms of drug binding remain unclear. Here, we describe the molecular evolution of sGC, new molecular models, and the linked equilibria between sGC NO binding, drug binding, and catalytic activity. Future Directions: Recent results and ongoing studies lay the foundation for a complete understanding of structure and mechanism, and they open the door for new drug discovery targeting sGC. Antioxid. Redox Signal. 26, 107-121.
AB - Significance: Soluble guanylyl/guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) and is central to the physiology of blood pressure regulation, wound healing, memory formation, and other key physiological activities. sGC is increasingly implicated in disease and is targeted by novel therapeutic compounds. The protein displays a rich evolutionary history and a fascinating signal transduction mechanism, with NO binding to an N-terminal heme-containing domain, which activates the C-terminal cyclase domains. Recent Advances: Crystal structures of individual sGC domains or their bacterial homologues coupled with small-angle x-ray scattering, electron microscopy, chemical cross-linking, and Förster resonance energy transfer measurements are yielding insight into the overall structure for sGC, which is elongated and likely quite dynamic. Transient kinetic measurements reveal a role for individual domains in lowering NO affinity for heme. New sGC stimulatory drugs are now in the clinic and appear to function through binding near or directly to the sGC heme domain, relieving inhibitory contacts with other domains. New sGC-activating drugs show promise for recovering oxidized sGC in diseases with high inflammation by replacing lost heme. Critical Issues: Despite the many recent advances, sGC regulation, NO activation, and mechanisms of drug binding remain unclear. Here, we describe the molecular evolution of sGC, new molecular models, and the linked equilibria between sGC NO binding, drug binding, and catalytic activity. Future Directions: Recent results and ongoing studies lay the foundation for a complete understanding of structure and mechanism, and they open the door for new drug discovery targeting sGC. Antioxid. Redox Signal. 26, 107-121.
KW - H-NOX domain
KW - coiled-coil domain
KW - guanylate cyclase
KW - hypertension
KW - molecular evolution
KW - stimulator compound
UR - http://www.scopus.com/inward/record.url?scp=85009400062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009400062&partnerID=8YFLogxK
U2 - 10.1089/ars.2016.6693
DO - 10.1089/ars.2016.6693
M3 - Review article
C2 - 26979942
AN - SCOPUS:85009400062
SN - 1523-0864
VL - 26
SP - 107
EP - 121
JO - Antioxidants and Redox Signaling
JF - Antioxidants and Redox Signaling
IS - 3
ER -